抑癌基因RASSF1A在胰腺癌组织中表达的研究

目的：探讨抑癌基因RASSF1A在胰腺癌组织中的表达及其与胰腺癌发生、发展的关系。方法：采用免疫印迹方法检测48例胰腺癌组织及其癌旁（正常）组织RASSF1A基因蛋白的表达水平。结果：癌旁组织RASSF1A蛋白的表达量高于高分化腺癌组织的表达量（P<0.05);高分化腺癌组织RASSF1A蛋白的表达量高于中、低分化腺癌组织（P<0.05)。TNM分期Ⅲ期RASSF1A蛋白的表达量低于Ⅰ,Ⅱ期(P<0.05)。RASSF1A基因蛋白表达与性别、年龄,肿瘤发生部位无明显关系(P>0.05)。结论：RASSF1A表达缺失或低下在胰腺癌的发生、发展中起重要作用。     

超声多普勒引导下的痔动脉结扎治疗痔病进展

20世纪KapullerLL．ThulesiusO等人就对痔动脉血流和动静脉吻合在痔病的发生机制中的作用进行了研究,而GalkinEV等人利用此理论从1994年开始陆续报道应用x线下直肠上动脉远端分支高选择性血管栓塞术治疗痔病,     

胰头癌58例根治术后生存分析

目的 探讨胰头癌根治术后长期生存的影响因素.方法 回顾性分析我院1996年1月至2004年1月58例胰头癌根治术患者的临床资料,并以SPSS10.0统计软件包行COX多元回归分析.结果 58例胰头痛根治性切除术患者中,男30例,女28例,均为胰腺导管癌.行标准胰十二指肠切除术14例,扩大根治术44例.全组1、3、5年生存率为46.6%(27/58)、29.3%(17/58)和8.6%(5/58).扩大根治术组1、3、5年生存率分别为43.2%(19/44)、22.7%(10/44)和6.8%(3/44).COX多元回归分析表明UICC分期、胰周神经浸润和围术期输血对预后有显著影响.结论 胰头癌根治性切除术后长期生存率仍不理想,应重视早期诊断和综合治疗措施.     

腹腔镜胆囊切除术74l例临床分析

目的 探讨741例腹腔镜胆囊切除术(LC)经验，以提高LC的成功率，减少LC并发症。方法 总结分析1997年9月至2002年3月在我院收治的741例腹腔镜胆囊切除术病例。结果 741例比均获痊愈，手术并发症发生率2．43％，中转开腹10例(1．35％)，随访2—51个月，预后佳。结论 严格地掌握LC的适应证，术中审慎操作，及时中转开腹是有效减少LC并发症的重要手段。     

早期肠内营养联合生大黄对大鼠急性坏死性胰腺炎肝损伤的影响

目的探讨早期肠内营养(EEN)联合生大黄对实验性急性坏死性胰腺炎(ANP)大鼠肝损伤的影响。方法48只雄性Wistar大鼠随机分为ANP组、生大黄组、EEN组及EEN联合生大黄组(联合组),每组12只。各组于造模后48h测定血肿瘤坏死因子(TNF-α)、内毒素(LPS)、谷丙转氨酶(ALT)、谷草转氨酶(AST)、C反应蛋白(CRP)、丙二醛(MDA)含量;检测肝脏组织髓过氧化物酶(MPO)活性。结果与ANP组相比,其他3组的各项指标均有显著差异;联合组血TNF-α[(1.38±0.17)ng/ml]、内毒素[(0.114±0.048)EU/ml]、ALT[(90.95±55.67)U/L]、AST[(203.12±36.92)U/L]、CRP[(41.2±22.6)mg/L]、MDA[(4.78±1.55)nmol/ml]浓度及肝脏组织MPO活性[(3.95±0.71)U/g]均较生大黄素组与EEN组显著降低(P<0.05)。结论EEN联合生大黄可有效减轻ANP并发的肝损伤程度,其机制可能与保护肠黏膜屏障功能、改善肝脏微循环障碍、抑制肝脏急性炎症反应、氧化反应和肝细胞凋亡等作用有关。     

重症急性胰腺炎术后并发胃十二指肠瘘的诊治

目的 探讨SAP术后并发胃十二指肠瘘的原因、形成机制、诊断和治疗经验.方法 收集1996年1月至2007年12月期间收治的18例SAP术后并发胃十二指肠瘘患者的临床资料进行回顾性分析.结果 18例SAP患者,4例行胆囊切除、胆总管切开取石术,4例行胰腺坏死组织清除术及开放式蝶式引流,10例行胰腺坏死组织清除,胰床松动及腹腔闭式引流.其中发生十二指肠瘘12例(66.7%),胃瘘6例(33.3%),发生于术后3周之内14例(77.8%).术后3周之后4例(22.2%).16例(88.9%)经引流、冲洗脓腔、抗感染等非手术治疗均获治愈,平均住院时间65 d.2例(11.1%)分别死于腹腔内出血、腹腔感染并发腹腔间室隔综合征(ACS)和MODS.结论 SAP术后并发胃十二指肠瘘经过恰当的非手术治疗是可以获得痊愈的.     

异位胰腺的诊断与治疗:附35例病例报告

目的探讨异位胰腺的临床特点、诊断方法及外科处理原则。方法对我院自1996年7月至2006年8月经病理确诊的35例异位胰腺病人的临床特点、影像资料及治疗方法进行回顾性分析。结果本组35例病人中男16例，女19例，年龄18个月至74岁，平均43.5岁。单发33例，多发2例。异位胰腺分布部位：胃13例，十二指肠5例，空肠6例，结肠6例，胆囊、胆总管、后腹膜各1例，回、升结肠并发2例。术前仅6例确诊，8例误诊，21例漏诊。全组均经病理证实，4例内镜下高频电灼或电凝切除，31例手术治疗。随访2.4～8年，无一例出现术后并发症。结论异位胰腺的临床表现无特异性，易漏诊和误诊，内镜超声的临床应用能显著地提高诊断率。异位胰腺一旦出现症状，需早期内镜电凝或电切和手术治疗，以明确诊断及避免出现严重的并发症。无症状者无需治疗但应加强随访。     

大黄辅助早期肠内营养对急性坏死性胰腺炎病程影响的研究

Objective To investigate the effect of rhubarb assisted early enteral nutrition (EEN) on acute necrotizing pancreatitis(ANP) in rats. Methods A total of 48 Wistar rats were ran-domized into 4 groups(n=12) including ANP group (group A), rhubarb group (group B), EEN group (group C) and rhubarb assisted EEN (RAEEN) group (group D). The rats in group B, C and D were infused with rhubarb, enteral nutrient solution and enteral nutrient solution plus rhubarb by enteral nutrient canal after establishing the model, respectively. The remaining living animals in each group were sacrificed 48 hours after ANP models were developed to determine the tumor necrosis fac-tor-alpha (TNF-α), endotoxin, D-lactate, maleic dialdehyde (MDA), angiotensin Ⅱ (Ang Ⅱ) in ser-um. The intestinal secretory IgA (SIgA), the amount of ascitic fluid and the wet-dry weight ratio of ileum, the pancreatic Myeloperoxidase (MPO) activity as well as the wet-dry weight ratio of pancreas were determined and the pathologic changes of pancreas were analyzed by histopathologic grading and scoring of the severity of pancreas. Results Compared with group A, group B, C and D had signifi-cant difference in every index (P<0. 05). Furthermore, compared with rhubarb and EEN, RAEEN significantly increased the level of intestinal SIgA but reduced the other data obviously (P<0. 05). Conclusion Administration of RAEEN can effectively protect the intestinal barrier function, improve the organismic immunity, inhibit the systemic inflammatory reaction and ameliorate the microcirculato-ry disorders in ANP. The combined strategy is more safe and effective than either one alone.     

二氢青蒿素对胰腺癌生长的抑制作用

Objective To investigate the anti-tumor activity of dihydroartemisinin in pancreatic cancer in vitro and in vivo. Methods For cultured cells,cell growth was determined by the MTT assay and apoptosis was evaluated by flow cytometry analysis stained with Annexin V-FITG/PI. The protein expression in BxPC-3 cells was analyzed by Western blot assay. BxPC-3 cells were injected subcutaneously into nude mice to establish pancreatic xenograft tumors and the tumor volume was monitored after exposure to dihydroartemisinin. Ki-67 staining and TUNEL assay were used to assess tumor cell proliferation and apoptosis in tumor tissue. Results After treatment by dihydroartemisinin in vitro, the proliferative inhibition rates of pancreatic cancer cells BxPC-3 and AsPC-1 reached up to (76.2 ± 3.5) % and (79.5 ± 2.9) %, and the apoptosis rates were up to (55.5 ± 3.2)% and (40.0 ± 3.5)%, the differences were significantly (P ＜ 0.01) compared with control [(2.0 ± 1.3) % and (0.9 ± 0.4) %]. Dihydroartemisinin inhibited the growth of pancreatic xenograft tumors in nude mice. The proliferation index and apoptusis index were (49.1 ± 3.9)% and (50.2 ± 4.4)% respectively in dihydroarternisinin 50 mg/kg treatment group, compared to those of (72.1 ± 3.3) % and (9.4 ± 2.9) % in control, the differences were significantly (P ＜0.01). Western blot assay indicated that dihydroartemisinin up-regulates expression of proliferation-associated protein p21WAF1 and down-regulates expression of PCNA, increases expression of apoptosis-associated protein Bax and decreases expression of Bcl-2 and activates caspase-9 in BxPC-3 cells. Conclusions Dihydroartemisinin exerts anti-tumor activity in pancreatic cancer both in vitro and in vivo by proliferation inhibition and apoptusis induction. Dihydroartemisinin can be used as a potential anti-tumor drug in pancreatic cancer.